- Trials with a EudraCT protocol (102)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
102 result(s) found for: Abdominal discomfort.
Displaying page 4 of 6.
EudraCT Number: 2010-018902-35 | Sponsor Protocol Number: TC-6499-12-CLP-004 | Start Date*: 2010-05-05 | |||||||||||
Sponsor Name:Targacept Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Proof of Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominan... | |||||||||||||
Medical condition: Constipation Predominant Irritable Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000604-16 | Sponsor Protocol Number: ARD6772 | Start Date*: 2006-08-30 |
Sponsor Name:sanofi-aventis recherche & développement | ||
Full Title: A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites. | ||
Medical condition: Advanced ovarian cancer patients with recurrent symptomatic malignant ascites. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002924-17 | Sponsor Protocol Number: A3384-001 | Start Date*: 2014-01-27 |
Sponsor Name:Albireo AB | ||
Full Title: A double-blind, randomized, placebo-controlled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsor... | ||
Medical condition: Patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-003827-45 | Sponsor Protocol Number: MA39293-DIET | Start Date*: 2017-12-21 | |||||||||||
Sponsor Name:CIBER - Instituto Carlos III [...] | |||||||||||||
Full Title: AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001245-32 | Sponsor Protocol Number: PGX-III-AP-002 | Start Date*: 2011-10-19 | |||||||||||
Sponsor Name:Forest Laboratories, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) | |||||||||||||
Medical condition: Coronary Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003770-14 | Sponsor Protocol Number: 3030-202-002 | Start Date*: 2018-10-11 | ||||||||||||||||
Sponsor Name:Allergan LTD | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irrit... | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) NL (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022991-29 | Sponsor Protocol Number: SMR/0211OBD-1033 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:Sucampo Pharma Americas, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction | |||||||||||||
Medical condition: Opioid-induced Bowel Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000733-39 | Sponsor Protocol Number: ABX464-104 | Start Date*: 2019-11-21 | |||||||||||
Sponsor Name:ABIVAX | |||||||||||||
Full Title: A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis. | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) AT (Completed) SI (Completed) BE (Completed) CZ (Completed) ES (Ongoing) HU (Completed) GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004676-37 | Sponsor Protocol Number: GD3-170-302 | Start Date*: 2005-04-27 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea | |||||||||||||
Medical condition: C. difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002923-24 | Sponsor Protocol Number: R033812GTS3001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects Wi... | |||||||||||||
Medical condition: Nausea and Vomiting Due to Acute Gastroenteritis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PT (Completed) BE (Completed) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016973-13 | Sponsor Protocol Number: LX1606.1-203-CS | Start Date*: 2010-03-08 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome | |||||||||||||
Medical condition: Symptomatic Carcinoid Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004398-30 | Sponsor Protocol Number: ABX464-108 | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Abivax | |||||||||||||
Full Title: A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) SI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000998-39 | Sponsor Protocol Number: TIDE-13-22 | Start Date*: 2014-10-30 | |||||||||||
Sponsor Name:Helsinn Healthcare SA | |||||||||||||
Full Title: Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. el... | |||||||||||||
Medical condition: Chemotherapy Induced Diarrhea (CID) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004997-23 | Sponsor Protocol Number: M0003-C201 | Start Date*: 2007-11-23 | |||||||||||
Sponsor Name:Movetis NV | |||||||||||||
Full Title: An exploratory, double-blind, randomized, stratified, placebo-controlled, repeated dose trial to investigate the efficacy of M0003 on symptoms suggestive for gastroparesis, to assess the pharmacody... | |||||||||||||
Medical condition: Symptoms suggestive for gastroparesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) LT (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004934-42 | Sponsor Protocol Number: PM L 0161 | Start Date*: 2006-04-13 | |||||||||||
Sponsor Name:SANOFI-AVENTIS OTC | |||||||||||||
Full Title: Efficacy evaluation of Enterogermina, 2 billion Bacillus clausii spores, on eradication of small intestinal bacterial overgrowth a randomised, parallel-group, open study | |||||||||||||
Medical condition: irritable bowel syndrome according to Rome II criteria and small intestinal bacterial overgrowth | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005180-25 | Sponsor Protocol Number: NM/BL-IIa-1106 | Start Date*: 2006-12-15 | |||||||||||
Sponsor Name:Nordmark Arzneimittel GmbH | |||||||||||||
Full Title: A study investigating the safety, tolerability and pharmacodynamics of bacterial lipase in patients with cystic fibrosis and pancreatic insufficiency Randomized, double-blind, placebo-controlled, s... | |||||||||||||
Medical condition: Caucasian males aged between 18 and 50 years of age (inclusive) with cystic fibrosis and pancreatic insufficiency able to discontinue their standard pancreatic enzyme therapy during the treatment p... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002087-10 | Sponsor Protocol Number: 1062.7 | Start Date*: 2007-08-28 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administere... | |||||||||||||
Medical condition: To compare the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops to placebo in patients with functional constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003284-35 | Sponsor Protocol Number: ABX464-102 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:ABIVAX | |||||||||||||
Full Title: A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis. | |||||||||||||
Medical condition: Moderate to severe Ulcerative Colitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) PL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001321-31 | Sponsor Protocol Number: 24032020 | Start Date*: 2020-04-11 |
Sponsor Name:Hospital Universitario de Fuenlabrada | ||
Full Title: Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients wit... | ||
Medical condition: Pneumonia due to SARS Cov2 (COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003307-21 | Sponsor Protocol Number: 848016005-02 | Start Date*: 2018-05-30 |
Sponsor Name:Maastricht University | ||
Full Title: Tailored treatment of functional dyspepsia with nortriptyline: a multi-center double-blind placebo-controlled trial (TENDER) | ||
Medical condition: Functional dyspepsia (FD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
